Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Preliminary ruling: REACh regulation of monomers in polymers required
On March 10, a preliminary ruling by the European Court of Justice would require registration under REACh of reacted monomers in polymers. Juliane Kokott one of the Advocate
On March 10, a preliminary ruling by the European Court of Justice would require registration under REACh of reacted monomers in polymers. Juliane Kokott one of the Advocate
“In recent years, life-saving diagnostic lab tests have been developed that can help doctors clarify inconclusive diagnoses and tailor treatments according to individual patient’s DNA and the specific
SPBS provides preventive maintenance, electrical safety, full service agreements, and performance testing inspections to enhance the healthcare organizations equipment reliability and performance as well as satisfying Medicare, AAAHC,
Under the terms of the purchase agreements, PharmAthene will sell an aggregate of 2.12 million newly issued shares of its common stock at $2.60 per share and warrants
The trial met its primary efficacy endpoint, the mean change from baseline to week 12 (or last visit) of average weekly pain intensity scores, and the results were
“Prometheus had another record year in 2008, our 12th consecutive year of sales growth,” said Joseph M. Limber, President And Chief Executive Officer of Prometheus. “In addition, we
Vetter Pharma-Fertigung, a provider of aseptically pre-filled injection systems, has formed a new subsidiary, Vetter Pharma International. With a scheduled launch date of April 1, 2009, Vetter Pharma
GVK Biosciences, an Indian contract research organization, has obtained approval from the Ministry of Health of Turkey for bioequivalence studies. This approval enables GVK Biosciences to cater to
The companies will also continue joint product development activities ensuring customers have continued access to new coagulation technology. “Our shared value to deliver quality products and services that
Net sales for the fourth quarter of 2008 were $2.2 million, down $1.2 million, or 31.6% from $3.3 million reported in the fourth quarter of 2007. Operating loss